Large Molecule Quantification

Address the quantification of peptide- and protein-based biotherapeutics and biomarkers.

Sign up to receive updates

Meeting the Challenges of Large Molecule Bioanalysis: Demonstration of an Automated & Standardized, Kit-Based Workflow for LC-MS/MS Protein Quantification

This poster presented at 65th ASMS Conference from June 4-8 in Indianapolis, IN.

A Generic Kit-Based Approach for LC-MS/MS Quantifcation of Urinary Albumin for Clinical Research

2017 WRIB Poster

Sensitive and Reproducible LC-MS Quantification of C-Reactive Protein in Plasma for Clinical Research

2017 WRIB Poster

A Leading CRO's Customer Focus Leads to Improvements in Quality and Productivity

Triskelion, a TNO company, demonstrates how they provide leading edge quality through a combination of service, skills, and technology.

Peptide Optimization Using Skyline and the Xevo TQ-XS

This technology brief demonstrates the workflow for peptide MRM optimization using the Xevo TQ-XS Triple Quadrupole Mass Spectrometer, Skyline software and phosphorylation B peptide standard.

Why Should Bioanalysts Use Microflow LC-MS?

Why are scientists at leading companies like GlaxoSmithKline, Merck, and Pfizer using microflow LC-MS for more routine applications? The answer is simple: an overarching need to do more with less. They are working with more complex analytes, with limited sample, often requiring both improved sensitivity and high throughput. Although microflow LC-MS has been perceived as a tradeoff between high sensitivity and throughput, recent advances are yielding flexible systems that enable analysts to collect highly sensitive data with cycle times comparable to analytical scale.

LC-MS/MS Quantification of Intact Insulin-Like Growth Factor-1 for Clinical Research

Insulin like Growth Factor I (IGF-I) is a 70 amino acid peptide hormone which plays a significant role in mediating the effects of Growth Hormone (GH). The pulsatile nature of secretion and fluctuation of levels due to sleep, food, exercise etc make GH a less reliable biomarker. IGF-I has been used as a supplementary or surrogate marker for growth related abnormalities. In recent years, use of IGF-I as a marker for GH related doping cases has also been reported.

IGF-I is a 7.6kDa protein, with 3 internal di-sulphide bonds. It is found in circulation throughout the body as a complex bound to one of 6 binding proteins, the most significant of which is IGF binding protein 3 (IGF-BP3).

Historically, immunoassays have been used for quantification of IGF-I from human biological matrices. Immunoassays have been shown to lack specificity due to their potential inability to distinguish between closely related IGF isoforms. In recent years, LC-MS based approaches for the quantification of IGF-I have been reported, which utilize either the surrogate peptide approach to quantify signature peptides on a tandem quadrupole instrument, or measure intact IGF-I using a nano-UPLC/HRMS system. Affinity enrichment approaches have also been utilized to clean up the samples before quantification. Both these approaches require significant time and resources in the sample preparation phase adding cost and complexity to the analysis.

A simplified workflow for quantification of intact IGF-I from human serum on a tandem quadrupole instrument is highlighted in this poster.